Report ID: 10078299 |
Published Date: 21 Oct 2022 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
Global Diabetes Drug Industry was valued at USD 47.1 Billion in the year 2017. Global Diabetes Drug Industry is further estimated to grow at a CAGR of 7.1% from 2019 to reach USD 81.30 Billion by the year 2025. North America region holds the highest Industry share in 2017 and Asia-Pacific is considered as the fastest growing Industry in the forecasted period. At a country level, developed industries the U.S. holds a substantial Industry share in 2017 and it is projected to grow at a gradual pace in the coming years.
Major market players in Diabetes Drugs Industry are Abbott Laboratories, AstraZeneca PLC, Bayer Healthcare AG, Dexcom Inc., GlaxoSmithKline PLC, Johnson & Johnson, Sanofi, Merck & Co., Novartis AG, Novo Nordisk, and another brief information of 10 companies will be provided in the report. Industry share because of its better global presence both at production and at an operational level. Rising research and development expenses to address the changing demand of end users. Similarly, growth strategies such as acquisition, merger, and expansion of the distribution network were few techniques adopted by most of the top players in the last 5 years.
SWOT Analysis of Diabetes Drug Industry:
Strength:
Improved diagnosis and advances in treatment
Increasing diabetic population
Weakness:
Lack of awareness among people
Increased Risk of Cardiovascular Complications
Opportunities:
Launching of advance and new Anti-Diabetes Drugs
High growth opportunity in the Emerging Industry
Threats:
Other emerging therapy industries
Patent Expiries and Rising Competition of Generic Drugs
The global diabetes drug Industry id segmented on the basis of products & services, by application and by region. On the basis of products and services, the Insulin Derivative segment is expected to hold the highest Industry share during the forecast period. Due to its high price, rising geriatric population and need & demand for insulin.
Diabetes Drug Industry Segmentation:
By Application
• Type 1 Diabetes
• Type 2 Diabetes
By Products & Services
• Insulin Derivatives
o Rapid-acting insulin
o Intermediate-acting insulin
o Long-acting insulin
• Oral Diabetic Medication Drugs
o Sulfonylurea
o Metformin
o Alpha-Glucosidase inhibitor
o Thiazolidinediones
o Biguanide
o Meglitinides
o GPP4-Inhibitors
o GLP-1
By Region
North America
• USA
• Canada
Europe
• Germany
• U.K.
• France
• Italy
• Rest of Europe
APAC
• China
• India
• Japan
• Rest of Asia-Pacific
RoW
• Latin America
• Middle East & Africa
1
Why Choose Kenneth Research ?
-
Insight with Impact : We don’t just gather data — we uncover stories, trends, and opportunities that fuel business growth.
-
Experts Who Get It : Our team speaks your industry’s language and knows what really matters to your customers and market.
-
Custom-Built for You : Forget one-size-fits-all. We craft research and consulting solutions as unique as your business vision.
-
Partners, Not Just Providers : We work with you, not for you — collaborating closely to turn insights into smart, strategic moves.
-
Results That Speak : Our work powers brands, startups, and industry leaders alike — with a track record of ideas that work in the real world.
Report ID: 10078299 |
Published Date: 21 Oct 2022 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
